Press Release

The US Inhalation Systems Market to surpass $800 million by 2024

January, 2019

" "

The US inhalation systems market is expected to witness a CAGR of 5.8% to reach revenue of $851.5 million by 2024

Bangalore, India, December 21, 2018: With its recently published study US Inhalation Systems Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2024”, Infoholic Research forecasts that the US market for inhalation systems will continue to grow, owing to the increasing prevalence of the respiratory disease, favorable reimbursement, advancements in technology, upsurge in the geriatric population, and increase in the demand for home-care therapeutics devices.

Get a Sample Copy of the Report @

The US inhalation systems market, by products, is segmented into inhalers and nebulizers. By inhalers, the market is sub-segmented into dry powder inhalers and metered dose inhalers. By nebulizers, the market is segmented into ultrasonic nebulizer, pneumatic nebulizer, and mesh nebulizer. The increased usage of inhalers in the therapy of asthma, chronic obstructive pulmonary disorder, and other respiratory illness made the inhalers segment the major shareholder in 2017. The nebulizers segment is expected to grow at a high CAGR during the forecast period because of the increase in demand for these systems due to the increasing prevalence of COPD.

On the basis of end-users, the US inhalation systems market is segmented into hospitals, ambulatory care centers, and home care. Currently, hospitals hold a major share in the market, but the fastest growth is seen in the home care segment due to comfort in the usage of newest products, availability of reimbursement, and less homecare cost.

Access Full Report Summary @
“The inhalation systems market in the US is gradually growing with an upsurge in the investment for developing innovative systems and increasing product approvals, which can enhance the position of the market players. For instance, in February 2017, Boehringer Ingelheim announced the US FDA approval of SPIRIVA RESPIMAT to treat asthma patients of age 6 years and older. The growing prevalence of the respiratory disease is expected to provide a better opportunity for the increase in the use of these systems.” said Arpitha Shetty, Research Analyst, Infoholic Research

Key Insights of the Report Include:

  • By Products:

    • Inhalers

  • Dry Powder Inhalers

  • Metered Dose Inhalers

    • Nebulizers

  • Ultrasonic Nebulizers

  • Pneumatic Nebulizers

  • Mesh Nebulizers

  • By Applications:

    • Asthma

    • Chronic Obstructive Pulmonary Disease (COPD)

    • Others

  • By End-users:

    • Hospitals

    • Ambulatory Care Centers

    • Home Care

  • Industry outlook: Market trends, drivers, restraints, and opportunities


Mr. Karthick Subramani

Infoholic Research LLP

Marketing & Communication